Anti-thrombotic therapy for elderly patients with acute coronary syndromes

Coronary Artery Disease

Volumn 11, Issue 4, 2000, Pages 323-330

  Chen, Ya Ting ^a   Tuohy, Edward R ^a   Krumholz, Harlan M ^a,b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b QUALIDIGM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRUDIN; LAMIFIBAN; LOW MOLECULAR WEIGHT HEPARIN; TIROFIBAN; XEMILOFIBAN;

ACUTE HEART INFARCTION; ADULT; AGED; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; PRIORITY JOURNAL; REVIEW; UNSTABLE ANGINA PECTORIS;

ANGINA, UNSTABLE; ANTICOAGULANTS; ASPIRIN; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RANDOMIZED CONTROLLED TRIALS; SYNDROME; THROMBOLYTIC THERAPY; TREATMENT OUTCOME;

EID: 0034087789     PISSN: 09546928     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019501-200006000-00005     Document Type: Review

References (47)

1. 1 Fuster V, Badimon L, Badimon JJ, Chessebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes (first of two parts). N Engl J Med 1992; 326:242-250. An excellent review of the mechanism and pathogenesis of acute coronary syndromes.
2. 2 Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes (second of two parts). N Engl J Med 1992; 326:310-318. An excellent review of the mechanism and pathogenesis of acute coronary syndromes.
3. 3 Udvarhelyi IS, Gatsonis C, Epstein AM, Pashos CL, Newhouse JP, McNeil BJ. Acute myocardial infarction in the Medicare population. JAMA 1992; 268:2530-2536.
4. 4 Graves EJ. National hospital discharge survey: annual summary 1991. Washington: Public Health Service; National Center for Health Statistics; 1993.
5. 5 Luchi RJ, Taffet GE, Teasdale TA. Congestive heart failure in the elderly. J Am Geriatr Soc 1991; 39:810-825.
6. 6 Wei JY. Age and the cardiovascular system. N Engl J Med 1992; 327:1735-1739. This is an interesting review of the impact of aging on changes in the cardiovascular system.
7. 7 ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17 187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; ii:349-360. This study was the first large randomized clinical trial demonstrating that aspirin was clinically efficacious in treating 17 187 patients suspected to have suffered acute myocardial infarction. The authors found a 23% lower 5-week mortality from vascular causes among patients allocated to the aspirin group than for the placebo group.
8. 8 Baigent C, Collins R, Appleby P, Parish S, Sleight P, Peto R. ISIS-2: 10 years survival among patients with suspected acute myocardial infarction in randomized comparison of intravenous streptokinase, oral aspirin, both, or neither. BMJ 1998; 316:1337-1343.
9. 9 Lewis HD Jr, Davis JW, Archibald DG, Steinke WE, Smitherman TC, Doherty JE, et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study. N Engl J Med 1983; 309:396-403.
10. 10 Cairns JA, Gent M, Singer J, Finnie KJ, Frogatt GM, Holder DA, et al. Aspirin, sulfinpyrazone, or both in unstable angina. Results of a Canadian Multicenter trial. N Engl J Med 1985; 313:1369-1375.
11. 11 Theroux P, Ouimet H, McCans J, Latour JG, Joly P, Levy G, et al. Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med 1988; 319:1105-1111.
12. 12 Antiplatelet Trialists' Collaboration. Collaborative overview of randomized trials of antiplatelet therapy - I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308:81-106. This article is a comprehensive overview of the clinical efficacy of prolonged use of antiplatelet therapy (for 1 month or more). The authors concluded that some years of antiplatelet therapy offer worthwhile protection against myocardial infarction, strokes and death for a much wider range of patients at high risk of occlusive vascular disease than is currently treated routinely.
13. 13 Krumholz HM, Radford MJ, Ellerbeck EF, Hennen J, Meehan TP, Petriud MK, et al. Aspirin in the treatment of acute myocardial infarction in elderly Medicare beneficiaries: patterns of use and outcomes. Circulation 1995; 92:2841-2847. Authors of this article describe the current pattern of use of aspirin and its effectiveness in treating a large population-based sample of elderly patients with AMI. The authors conclude that aspirin was underused in treating elderly patients with AMI; the use of aspirin was associated with a 22% lower probability of death within 30 days.
14. 14 Krumholz HM, Philbin DM Jr, Wang Y, Vaccarino V, Murillo JE, Therrien ML, et al. Trends in the quality of care for Medicare beneficiaries admitted to the hospital with unstable angina. J Am Coll Cardiol 1998; 31:957-963. Authors of this study describe the current use of aspirin and heparin in treating elderly patients hospitalized with unstable angina between 1993 and 1995. The authors found that, although the use of aspirin and heparin had increased significantly over time, which was correlated to a concomitant significant reduction in readmission within 30 days, aspirin and heparin were underused in treating the elderly.
15. 15 Ellerbeck EF, Jencks SF, Radford MJ, Krewosik TF, Craig AS, Gold JA, et al. Quality of care for Medicare patients with acute myocardial infarction. JAMA 1995; 273:1509-1514. Authors of this article demonstrate that many elderly patients are not necessarily ideal candidates for standard AMI therapies, but these treatments are nonetheless underused, even in the absence of discernible contraindications to their use.
16. 16 Lamas GA, Pfeffer MA, Hamm P, Wertheimer J, Rouleau JL, Braunwald E. Do the results of randomized trials of cardiovascular drugs influence medical practice? N Engl J Med 1992; 327:241-247.
17. 17 Ryan TJ, Anderson JL, Antman EM, Braniff BA, Brooks NH, Califf RM, et al. ACC/AHA guidelines for the management of patients with acute myocardial infarction: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). J Am Coll Cardiol 1996; 28:1328-1428.
18. 18 Braunwald E, Brown J, Cheitlin MD, Concannon CA, Cowan M, Edwards C, et al. Clinical practice guideline number 10 (amended), unstable angina: diagnosis and management. Rockville, MD: USA Department of Health and Human Services, Agency for Health Care Policy and Research and the National Heart, Lung, and Blood Institute, Public Health Service; 1994.
19. 19 Collins R, MacMahon S, Flather M, Baigent C, Remvig L, Mortensen S, et al. Clinical effects of anticoagulant therapy in suspected acute myocardial infarction: systematic overview of randomized trials. BMJ 1996; 313:652-659. The authors systematically reviewed and summarized results of 26 randomized clinical trials of anticoagulant therapy for suspected AMI, especially the clinical effects of adding heparin to aspirin treatment. They conclude that the clinical evidence does not justify the routine addition of either intravenous or subcutaneous administration of heparin to aspirin therapy in the treatment of AMI.
20. 20 RISC Group. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet 1990; 336:827-830.
21. 21 Theroux P, Waters D, Qiu S, McCans J, deGuise P, Juneau M. Aspirin versus heparin to prevent myocardial infarction during the acute phase of unstable angina. Circulation 1993; 88:2045-2048.
22. 22 Oler A, Whooley MA, Oler J, Grady D. Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. JAMA 1996; 276:811-815. The authors systematically reviewed results of six randomized trials to estimate the effect of aspirin plus heparin compared with aspirin therapy alone on the risk of myocardial infarction and death for patients with unstable angina. The findings of this meta-analysis are consistent with there being a 33% lower risk of myocardial infarction or death for patients with unstable angina treated with aspirin plus heparin than for those treated with aspirin alone. This evidence suggests that most patients with unstable angina should be treated with both heparin and aspirin.
23. 23 Krumholz HM, Hennen J, Ridker PM, et al. Use and effectiveness ot intravenous heparin therapy for treatment of acute myocardial infarction in the elderly. J Am Coll Cardiol 1998; 31:973-979. Authors of this study focusing on old adults describe the use and effectiveness of heparin therapy for the treatment of AMI for 6935 patients aged 65 years and more in Alabama, Connecticut, Iowa, and Wisconsin from June 1992 through February 1993. The authors conclude that, although intravenous administration of heparin was commonly used (for 47% of those for whom there was no absolute contraindications to its use) for treatment of AMI of the elderly, it was not associated with an improvement in 30-day mortality rate.
24. 24 Harenberg J. Pharmacology of low molecular weight heparins. Semin Thromb Hemost 1990; 16 (suppl):12-18.
25. 25 Weitz JI. Low-molecular-weight heparins. N Engl J Med 1997; 337: 688-698. This is a comprehensive review of the current understanding of low-relative-molecular-mass heparin, including mechanisms, pharmacokinetics, results of clinical studies, and questions that remain unanswered.
26. 26 Fragmin During Instability in Coronary Artery Disease (FRISC) study group. Low-molecular-weight heparin during instability in coronary artery disease. Lancet 1996; 347:561-568.
27. 27 Klein W, Buchwald A, Hillis SE, Monrad S, Sanz G, Turpie AG, et al. Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease: Fragmin in Unstable Coronary Artery Disease Study (FRISC). Circulation 1997; 96:61-68.
28. 28 Cohen M, Demers C, Gurfinkel EP, Turpie AG, Fromell GJ, Goodman S, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med 1997; 337:447-452.
29. 29 Topol EJ, Fuster V, Harrington RA, Califf RM, Kleiman NS, Kereiakes DJ, et al. Recombinant hirudin for unstable angina pectoris: a multicenter, randomized angiographic trial. Circulation 1994; 89:1557-1566.
30. 30 The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIa Investigators. Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. Circulation 1994; 90:1631-1637.
31. 31 The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb Investigators. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N Engl J Med 1996; 335:775-782.
32. 32 Antman EM. Hirudin in acute myocardial infarction: safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A Trial. Circulation 1994; 90:1924-1930.
33. 33 Antman EM. Hirudin in acute myocardial infarction: Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B Trial. Circulation 1996; 94:911-921.
34. 34 Fuchs J, Cannon CP. Hirulog in the treatment of unstable angina. Circulation 1995; 92:727-733.
35. 35 The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994; 330:956-961.
36. 36 Lefkovits J, Ivanhoe RJ, Califf RM, Bergelson BA < Anderson KM, Stoner GL, et al. Effects of platelet glycoprotein IIb/IIIa receptor blockade by a chimeric monoclonal antibody (abciximab) on acute and six-month outcomes after percutaneous transluminal coronary angioplasty for acute myocardial infarction. Am J Cardiol 1996; 77:1045-1051.
37. 37 The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997; 336:1689-1696.
38. 38 The CAPTURE Investigators. Randomized placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study. Lancet 1997; 349:1429-1435.
39. 39 Tcheng JE, Harrington RA, Kottke-Marchant K, Kleiman NS, Ellis SG, Kereiakes DJ, et al. Multicenter, randomized, double-blind, placebo-controlled trial of the platelet integrin glycoprotein IIb/IIIa blocker integrelin in elective coronary intervention. Circulation 1995; 91:2151-2157.
40. 40 The IMPACT-II Investigators. Randomized placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT II. Lancet 1997; 349:1422-1428.
41. 41 Harrington RA. Design and methodology of the PURSUIT trial: evaluating eptifibatide for acute ischemic coronary syndromes. Am J Cardiol 1997; 80:34B-38B.
42. 42 The RESTORE Investigators. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation 1997; 96:1445-1453.
43. 43 The Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med 1998; 338:1498-1505.
44. 44 The Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med 1998; 338:1488-1497.
45. 45 Theroux P, Kouz S, Roy L, Knudtson ML, Diodati JG, Marquis JF, et al. Platelet membrane receptor glycoprotein IIb/IIIa antagonism in unstable angina: the Canadian Lamifiban Study. Circulation 1996; 94:899-905.
46. 46 The PARAGON Investigators. International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina. Circulation 1998; 97:2386-2395.
47. 47 Simpfendorfer C, Kottke-Marchant K, Lowrie M, Anders RJ, Burns DM, Miller DP, et al. First chronic platelet glycoprotein IIb/IIIa integrin blockade. A randomized, placebo-controlled pilot study of xemilofiban in unstable angina with percutaneous coronary interventions. Circulation 1997; 96:76-81.